GLP-1 Therapy Is Not the Whole Obesity Treatment: JAMA Calls for Multimodal, Lifelong Care: JAMA | October 2026

What Does This Article Emphasize?

The arrival of highly effective GLP-1–based therapies has transformed obesity treatment, but this JAMA article argues that medication should be one component of integrated, lifelong obesity care.

• Obesity is a chronic, relapsing disease, not an episodic problem solved by short-term weight loss.
• GLP-1 therapies improve weight, cardiometabolic risk and several obesity-related outcomes, but pharmacotherapy alone is not the optimal model of care.
• WHO evidence synthesis indicates that combining GLP-1 therapy + intensive behavioral therapy (IBT) produces greater weight reduction, cardiometabolic improvement and quality-of-life benefit than pharmacotherapy alone.
• IBT should include structured nutrition, physical activity and behavioral support, with sufficient intensity and duration for sustained change.
• Treatment goals should extend beyond kilograms lost to cardiometabolic health, functional capacity, quality of life and obesity-related complications.
• Multimodal care can incorporate pharmacotherapy, IBT, therapeutic nutrition and, when appropriate, metabolic/bariatric surgery or combination pharmacotherapy.
• Care should simultaneously address comorbidities including type 2 diabetes, cardiovascular and kidney disease, obstructive sleep apnea and MASLD.
• Long-term challenges—including drug discontinuation, weight regain and heterogeneous treatment response—require longitudinal follow-up rather than episodic prescribing.
• Primary care is proposed as the foundation for scalable obesity management, supported by multidisciplinary teams, registries, referral pathways and reliable medication access.
• Future research must determine the optimal sequencing and combination of GLP-1 therapies, surgery, behavioral interventions and treatments directed at individual comorbidities.

Why Does It Matter?

The GLP-1 era risks creating a new version of fragmented obesity care in which prescribing the drug becomes the treatment. The article instead reframes obesity management around whole-person outcomes and chronic-disease infrastructure.

GastroAGI Takeaway

The future of obesity care is not “GLP-1 versus lifestyle”—it is GLP-1 plus structured, longitudinal multimodal care.

For gastroenterologists and hepatologists, this is particularly relevant to MASLD/MASH: weight loss is only one therapeutic target. The broader goal is sustained improvement in metabolic health, liver disease and other obesity-related comorbidities, with treatment adapted over the patient's lifetime.

Evidence note: This is a JAMA perspective/review, not a new randomized trial; its recommendations synthesize WHO guidance and the existing evidence base rather than providing new comparative clinical outcomes.